939986-38-6 Usage
Uses
Used in Pharmaceutical Industry:
4-(6-Chloro-pyridin-3-ylMethoxy)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C16H23ClN2O3, MW: 326.82 is used as a building block for the development of new pharmaceutical compounds. Its unique structure, which includes a chloro-pyridine group and a tert-butyl ester, allows it to be a versatile component in the synthesis of a wide range of drugs.
Used in Research Applications:
In research settings, 4-(6-Chloro-pyridin-3-ylMethoxy)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C16H23ClN2O3, MW: 326.82 serves as an intermediate in the synthesis of various compounds. Its high purity makes it suitable for use in laboratory experiments, where it can be employed to explore the properties and potential applications of newly synthesized compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 939986-38-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,9,9,8 and 6 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 939986-38:
(8*9)+(7*3)+(6*9)+(5*9)+(4*8)+(3*6)+(2*3)+(1*8)=256
256 % 10 = 6
So 939986-38-6 is a valid CAS Registry Number.
939986-38-6Relevant academic research and scientific papers
ENZYME INHIBITORS
-
Page/Page column 45; 48; 61-62, (2021/02/26)
The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined h
BICYCLIC GPR119 MODULATORS
-
Page/Page column 41, (2012/06/15)
The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods o f treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR119 receptor by using either alone or in combinations of Formula (I)
